UroMedical PS AB
ABActiveOrg 5565166302Drottninggatan 97, 113 60 StockholmMedical specialists activities· NACE 8622Est. 1995 · 31 years old14 employees
Loading company…
Overview
UroMedical PS AB is a Swedish AB based in Stockholm, operating in the Medical specialists activities sector. Incorporated in 1995, the company has 14 employees and reported revenue of SEK 44.5m in its latest annual filing.
Revenue 2025
44.5M SEK
−10% vs 2024
EBITDA margin
23.6 %
−40% vs 2024
Net profit 2025
0M SEK
+100% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
1.4 %
Very weakAmong the 10% lowest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.5×
WeakAmong the 30% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
0.0 %
WeakAmong the 30% lowest rated companies in the industry
20212025
EBITDA — year on year
SEK millionsKey figures
Annual report 2025| Revenue | 44.5M SEK | -10% |
| EBITDA | 10.5M SEK | -40% |
| Net profit | 0M SEK | +100% |
| Total assets | 26.7M SEK | +62% |
| Equity | 0.4M SEK | 0% |
| Employees | 14 | — |
Company information
Legal name
UroMedical PS AB
Org number
5565166302
Legal form
Aktiebolag
NACE code
Founded
8 August 1995 · 31 years
Share capital
SEK 100,000
Employees
14 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av suppleanten i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva hälso- och sjukvård, utbildning inom sjukvårdsområdet samt handel med värdepapper och därmed förenlig verksamhet.
(no translation available)
Contact
Address
Drottninggatan 97, 113 60 Stockholm
Phone
+4619185655
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), UroMedical PS AB reported revenue of SEK 44.5m, a decrease of 10% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a break-even result, and the EBITDA margin stood at 23.6%.
At the end of 2025, equity financed 1.4% of the balance sheet, and current assets covered short-term debt 1.5 times.
Financials
Revenue
SEK millionsEBITDA
SEK millionsIncome statement
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44,468 | 49,212 | 44,673 | 42,502 | 36,100 |
| Staff expenses | -14,942 | -12,891 | -11,870 | -11,698 | — |
| EBITDA | 10,513 | 17,564 | 15,354 | 16,954 | 14,454 |
| Depreciation & amort. | -157 | -112 | -292 | -739 | -918 |
| EBIT | 10,355 | 17,452 | 15,063 | 16,215 | 13,536 |
| Net financials | 719 | -52,867 | 1,180 | 3,840 | 3,707 |
| Profit before tax | -2 | -31,315 | 0 | 9,899 | 13,607 |
| Tax | 2 | -4,604 | — | -2,114 | -2,831 |
| Net profit | 0 | -35,919 | 0 | 7,786 | 10,776 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
SEK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 26,709 | 16,490 | 72,417 | 69,673 | 49,689 |
| Equity | 380 | 380 | 36,299 | 36,299 | 28,513 |
| Long-term debt | — | — | — | — | 0 |
| Short-term debt | 17,153 | 6,933 | 22,841 | 18,201 | 5,008 |
| Total debt | 17,153 | 6,933 | 22,841 | 18,201 | 5,008 |
Financial ratios
5-year trendEBITDA margin
23.6 %
20212025
Equity ratio
1.4 %
Very weakAmong the 10% lowest rated companies in the industry
20212025
Return on equity
0.0 %
WeakAmong the 30% lowest rated companies in the industry
20212025
Net profit margin
0.0 %
Very weakAmong the 20% lowest rated companies in the industry
20212025
Asset turnover
1.66×
StrongAmong the 40% highest rated companies in the industry
20212025
Debt / equity
69.29×
Very weakAmong the 10% lowest rated companies in the industry
20212025
Sector performance
24 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginVery weak
Among the 20% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginAverage
Around the average of companies in the same industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginVery weak
Among the 20% lowest rated companies in the industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Weak
Among the 30% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 30% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 30% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 40% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Quick ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 20% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery weak
Among the 10% lowest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery weak
Among the 10% lowest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtWeak
Among the 30% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtAverage
Around the average of companies in the same industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery strong
Among the 20% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginWeak
Among the 30% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverStrong
Among the 40% highest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalWeak
Among the 40% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ER Chief Executive Officer | Chief Executive Officer | 2026 |
KK Chief Auditor | Chief Auditor | 2020 |
Former (4)
AG Audit | Audit | 2020 – 2020 |
ML External Signatory | External Signatory | 2020 – 2020 |
AU Chief Executive Officer | Chief Executive Officer | 2024 – 2026 |
FR Chief Executive Officer | Chief Executive Officer | 2020 – 2022 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
JK Chairman | Chairman | 2025 |
ER Board of Directors | Board of Directors | 2026 |
JW Deputy Board Member | Deputy Board Member | 2024 |
Former (13)
TH Board of Directors | Board of Directors | 2023 – 2023 |
KL Board of Directors | Board of Directors | 2020 – 2022 |
ØB Board of Directors | Board of Directors | 2023 – 2024 |
GL Board of Directors | Board of Directors | 2020 – 2022 |
KD Deputy Board Member | Deputy Board Member | 2020 – 2020 |
PB Chairman | Chairman | 2023 – 2023 |
AM Board of Directors | Board of Directors | 2022 – 2024 |
RG Chairman | Chairman | 2022 – 2022 |
AU Chairman | Chairman | 2023 – 2024 |
KJ Board of Directors | Board of Directors | 2024 – 2024 |
FR Chairman | Chairman | 2024 – 2025 |
EL Chairman | Chairman | 2022 – 2023 |
MH Chairman | Chairman | 2020 – 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 | |
| Company | 100% | 100% | 0001 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Armada Fund V Ky
UroMedical PS AB Board network connections
Board members of UroMedical PS AB also hold positions in 203 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Kristina Eriksson | Chief Auditor | 63 companiesMany roles |
| Anders Gunnar Pålhed | Audit | 54 companiesMany roles |
| Kurt Lennart Robertsson | Board of Directors | 17 companiesMany roles |
| Jonathan Kimber | Chairman | 12 companiesMany roles |
| Robert Gelmanovski | Chairman | 12 companiesMany roles |
| Fred Rosendal Helgesen | Chief Executive Officer | 11 companiesMany roles |
| Kim Daniel Dahl | Deputy Board Member | 9 companiesMany roles |
| Erik Rönnblad | Chief Executive Officer | 6 companiesMany roles |
| Jan-Olof Wiklund | Deputy Board Member | 6 companiesMany roles |
| Kurt Jonas Einar Hugosson | Board of Directors | 5 companies |
| Anna Ulrika Hansson | Chief Executive Officer | 3 companies |
| Anna Maria Kristina Frånlund | Board of Directors | 3 companies |
| Marie Louise Birgitta Agelin | External Signatory | 1 company |
| Gard Lauvsnes | Board of Directors | 1 company |
Frequently asked questions
What is the Org number of UroMedical PS AB?
UroMedical PS AB is registered with Bolagsverket / SCB under Org 5565166302.
What is the revenue of UroMedical PS AB?
UroMedical PS AB reported revenue of SEK 44.5m in 2025.
How many employees does UroMedical PS AB have?
UroMedical PS AB employs 14 people as of the latest annual report.
Who is the CEO of UroMedical PS AB?
Erik Rönnblad is the CEO of UroMedical PS AB, in role since 2026.
Who is the chairman of UroMedical PS AB?
Jonathan Kimber chairs the board of UroMedical PS AB, in role since 2025.
Where is UroMedical PS AB headquartered?
UroMedical PS AB's registered address is Drottninggatan 97 3tr.